{"id":"NCT02911935","sponsor":"Washington University School of Medicine","briefTitle":"Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II","officialTitle":"Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-11","primaryCompletion":"2021-04","completion":"2021-04","firstPosted":"2016-09-22","resultsPosted":"2022-06-07","lastUpdate":"2022-06-07"},"enrollment":200,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Respiratory Syncytial Virus, Bronchiolitis"],"interventions":[{"type":"DRUG","name":"Oral azithromycin","otherNames":["Azithromycin suspension"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Oral azithromycin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze during the preschool years.","primaryOutcome":{"measure":"Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze)","timeFrame":"Follow up duration of 18-48 months","effectByArm":[{"arm":"Azithromycin","deltaMin":45,"sd":null},{"arm":"Placebo","deltaMin":33,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.08"},{"comp":"OG000 vs OG001","p":"0.11"}]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["38237675","37621674"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":101},"commonTop":["Upper respiratory infection","Diarrhea","Ear infection","Vomiting","Rash"]}}